Preoperative Immune Cell Dysregulation Accompanies Ovarian Cancer Patients into the Postoperative Period
-
Published:2024-06-28
Issue:13
Volume:25
Page:7087
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Ulevicius Jonas1ORCID, Jasukaitiene Aldona1ORCID, Bartkeviciene Arenida1ORCID, Dambrauskas Zilvinas1ORCID, Gulbinas Antanas1ORCID, Urboniene Daiva2ORCID, Paskauskas Saulius3ORCID
Affiliation:
1. Laboratory of Surgical Gastroenterology, Institute for Digestive Research, Medical Academy, Lithuanian University of Health Sciences, A. Mickeviciaus g. 9, LT-44307 Kaunas, Lithuania 2. Department of Laboratory Medicine, Medical Academy, Lithuanian University of Health Sciences, A. Mickeviciaus g. 9, LT-44307 Kaunas, Lithuania 3. Department of Obstetrics and Gynecology, Medical Academy, Lithuanian University of Health Sciences, A. Mickeviciaus g. 9, LT-44307 Kaunas, Lithuania
Abstract
Ovarian cancer (OC) poses a significant global health challenge with high mortality rates, emphasizing the need for improved treatment strategies. The immune system’s role in OC progression and treatment response is increasingly recognized, particularly regarding peripheral blood mononuclear cells (PBMCs) and cytokine production. This study aimed to investigate PBMC subpopulations (T and B lymphocytes, natural killer cells, monocytes) and cytokine production, specifically interleukin-1 beta (IL-1β), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12 (IL-12), and tumor necrosis factor alpha (TNFα), in monocytes of OC patients both preoperatively and during the early postoperative period. Thirteen OC patients and 23 controls were enrolled. Preoperatively, OC patients exhibited changes in PBMC subpopulations, including decreased cytotoxic T cells, increased M2 monocytes, and the disbalance of monocyte cytokine production. These alterations persisted after surgery with subtle additional changes observed in PBMC subpopulations and cytokine expression in monocytes. Considering the pivotal role of these altered cells and cytokines in OC progression, our findings suggest that OC patients experience an enhanced pro-tumorigenic environment, which persists into the early postoperative period. These findings highlight the impact of surgery on the complex interaction between the immune system and OC progression. Further investigation is needed to clarify the underlying mechanisms during this early postoperative period, which may hold potential for interventions aimed at improving OC management.
Reference76 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021 2. Epidemiology and risk factors for ovarian cancer;Ali;Prz. Menopauzalny,2023 3. Fabbro, M., Colombo, P., Leaha, C.M., Rouanet, P., Carrère, S., Quenet, F., Gutowski, M., Mourregot, A., D’Hondt, V., and Coupier, I. (2020). Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. Cancers, 12. 4. Akter, S., Rahman, M.A., Hasan, M.N., Akhter, H., Noor, P., Islam, R., Shin, Y., Rahman, M.D.H., Gazi, M.S., and Huda, M.N. (2022). Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. Cells, 11. 5. Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression;Drakes;Adv. Exp. Med. Biol.,2021
|
|